Biolinerx Ltd ADR Down 11.54% To $1.15 After Earnings

BioLine RX Ltd - ADR (BLRX) surpassed earnings projections on 3/26/2024 for Q4 2023.

The consensus among analysts for Biolinerx Ltd ADR was for an earnings per share (EPS) loss of $0.22 per share. The firm was able to surpass those projections, reporting an EPS loss of $0.15 per share, a positive surprise of $0 (32%). Profits fell 88% year-over-year after reporting an EPS loss of $0.08 per share in its year-ago quarter. The negative growth rate signals that the Healthcare company isn't performing well amid current economic conditions.

Biolinerx Ltd ADR reported Q4 2023 revenue of $4.8 million. The $4.8 million (0%) negative revenue surprise led to 0% growth year-over-year as the firm reported revenue of $0.00 in its year-ago quarter. The lower earnings growth compared to revenue points to Biolinerx Ltd ADR not being able to improve its profit margin.

The stock is down 11.54% to $1.15 after the report.

The firm's higher revenue growth to earnings signals that the firm has not been able to reduce costs and has seen its profit margin decrease.

The average recommendation from Wall Street analysts was a Strong Buy which may get revised based on this new data.

Trading in the five days leading up to the report earned Biolinerx Ltd ADR a Bullish Sentiment Rank from InvestorsObserver.

Biolinerx Ltd ADR has performed a little below average during the past few months. Before the report, Biolinerx Ltd ADR received a Long-Term Technical Rank by InvestorsObserver of 25, putting it in the bottom half of stocks. The firm set a 52-week high on September 5, 2023 at $2.53 and set a 52-week low on March 27, 2023 at $0.79.

BioLine Rx Ltd is a clinical-stage biopharmaceutical development company with a strategic focus on oncology. Its development and commercialization pipeline consists of two clinical-stage therapeutic candidates - Motixafortide, a novel peptide for the treatment of solid tumors, hematological malignancies and stem cell mobilization, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, it has an off- strategy, a legacy therapeutic product called BL-5010 for the treatment of skin lesions.